On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech, Biogen) for the treatment of CD20-positive non-Hodgkin B-cell Lymphoma (NHL) and chronic lymphocytic…
Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and Waldentröm macroglobulinemia (WM); and for…
In celebration of his incredible accomplishments as a lymphoma researcher and doctor, his years of contributions to the lymphoma community, and his support of the Lymphoma Research Foundation (LRF), LRF will honor Anas Younes, MD with its Distinguished Leadership Award…
On July 10, the Lymphoma Research Foundation (LRF) is participating in a day of action in support of the Clinical Treatment Act, a bill that would provide Medicaid coverage of the routine care costs of clinical trials participation. Here is…
The Nation’s Premier Lymphoma-Specific Research Organization Also Adds Two Experts to Industry-Leading SAB NEW YORK (July 1, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the…
On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after at least two prior…
Largest Wine and Spirits Distributor in North America Receives LRF Award for Outstanding Commitment to Foundation’s Mission NEW YORK (June 7, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research…
Chicago Philanthropic Community Supports LRF’s Mission to Eradicate Lymphoma and Serve Those Impacted by this Blood Cancer CHICAGO – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma…
In a study funded in part by the Lymphoma Research Foundation, researchers find the loss of specific protein amplification and transcriptional reprogramming contribute to resistance to venetoclax for patients with B-cell lymphomas Researchers from Moffitt Cancer Center and Dana-Farber Cancer…
On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular…